Back to Search
Start Over
The Prognostic Role of On-Treatment Liver Stiffness for Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B
- Source :
- Journal of Hepatocellular Carcinoma
- Publication Year :
- 2021
- Publisher :
- Informa UK Limited, 2021.
-
Abstract
- Hye Won Lee,1– 3,* Hyun Woong Lee,4,* Jae Seung Lee,1– 3 Yun Ho Roh,5 Hyein Lee,3 Seung Up Kim,1– 3 Jun Yong Park,1– 3 Do Young Kim,1– 3 Sang Hoon Ahn,1– 3 Beom Kyung Kim1– 3 1Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea; 2Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Republic of Korea; 3Yonsei Liver Center, Severance Hospital, Seoul, Republic of Korea; 4Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea; 5Biostatistics Collaboration Unit, Department of Biomedical Systems Informatics, Yonsei University College of Medicine, Seoul, Republic of Korea*These authors contributed equally to this workCorrespondence: Beom Kyung KimDepartment of Internal Medicine, Yonsei University College of Medicine, 50-1 Yonsei-Ro, Seodaemun–Gu, Seoul, 03722, Republic of KoreaTel +82-2-2228-1930Fax +82-2-393-6884Email beomkkim@yuhs.acBackground: Dynamic changes in fibrosis markers occur under long-term antiviral treatment (AVT) for chronic hepatitis B. We evaluated prognostic values of on-treatment liver stiffness (LS) compared to ultrasonography findings and determined its optimal cutoff.Methods: The cumulative probability of hepatocellular carcinoma (HCC) was assessed among 880 patients receiving entecavir or tenofovir for ≥ 2 years. LS was measured using transient elastography.Results: After ≥ 2 years’ AVT, the proportion of patients with cirrhosis on ultrasonography decreased from 54.7% to 44.9% and the mean LS decreased from 13.6 to 8.2 kPa (both p< 0.001). However, unlike cirrhosis on ultrasonography before AVT (p< 0.001), that after ≥ 2 years’ AVT did not discriminate HCC risk (p=0.792). Using the Contal and O’Quigley’s method, pre-AVT and on-treatment LS of 12.0 and 6.4 kPa, respectively, were chosen as optimal cutoffs to successfully discriminate HCC risk (both p< 0.001). However, through stratification using both pre-AVT and on-treatment LS, the prognosis was finally determined according to on-treatment LS of 6.4 kPa, regardless of pre-AVT LS of 12.0 kPa. Using on-treatment LS of 12 kPa suggested by Caucasians with CHB receiving long-term AVT, patients with higher LS were more likely to develop HCC than those with lower LS (p=0.017); however, there was no significant difference between those with on-treatment LS of 6.4– 11.9 and ≥ 12.0 kPa (p=0.920).Conclusion: For HCC risk stratification in patients receiving long-term AVT, on-treatment LS cutoff should be lowered to 6.4 kPa, which is more predictive than 12 kPa or cirrhosis on ultrasonography. Further studies are required for validation.Keywords: antiviral treatment, hepatitis B, liver stiffness, hepatocellular carcinoma
- Subjects :
- medicine.medical_specialty
Cirrhosis
antiviral treatment
Gastroenterology
03 medical and health sciences
0302 clinical medicine
Liver stiffness
Fibrosis
Internal medicine
medicine
In patient
Journal of Hepatocellular Carcinoma
Original Research
business.industry
hepatocellular carcinoma
Entecavir
Hepatitis B
medicine.disease
liver stiffness
030220 oncology & carcinogenesis
Hepatocellular carcinoma
030211 gastroenterology & hepatology
hepatitis B
business
Transient elastography
medicine.drug
Subjects
Details
- ISSN :
- 22535969
- Volume :
- 8
- Database :
- OpenAIRE
- Journal :
- Journal of Hepatocellular Carcinoma
- Accession number :
- edsair.doi.dedup.....ef3e4bb92561f253bcd76624c8b09704